Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
56 hedge funds and large institutions have $37.3M invested in Carisma Therapeutics in 2020 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 16 increasing their positions, 11 reducing their positions, and 3 closing their positions.
367% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 3
45% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 11
24% more funds holding
Funds holding: 45 → 56 (+11)
16% more capital invested
Capital invested by funds: $32.3M → $37.3M (+$5.05M)
0.09% more ownership
Funds ownership: 0.98% → 1.07% (+0.09%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
54% less call options, than puts
Call options by funds: $80K | Put options by funds: $174K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.51M |
| 2 |
Renaissance Technologies
New York
|
+$1.13M |
| 3 |
Millennium Management
New York
|
+$808K |
| 4 |
Two Sigma Advisers
New York
|
+$734K |
| 5 |
Morgan Stanley
New York
|
+$556K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$383K |
| 2 |
Squarepoint
New York
|
-$274K |
| 3 |
Goldman Sachs
New York
|
-$145K |
| 4 |
Jane Street
New York
|
-$117K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$90.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PA
51
Parallel Advisors
San Francisco,
California
| $6K | -$533 | -21 | -9% |
|
|
KC
52
Kinloch Capital
Glen Allen,
Virginia
| $3K | +$2.54K | +100 | New |
|
53
UBS Group
Zurich,
Switzerland
| $2K | – | – | – |
|
|
RFA
54
Reilly Financial Advisors
La Mesa,
California
| $2K | +$837 | +33 | +60% |
|
55
Citigroup
New York
| $1K | – | – | – |
|
|
OSAM
56
O'Shaughnessy Asset Management
Stamford,
Connecticut
| $1K | +$1.01K | +40 | New |
|
|
57
Squarepoint
New York
| – | -$274K | -9,770 | Closed |
|
|
TSS
58
Two Sigma Securities
New York
| – | -$29K | -1,021 | Closed |
|
59
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1.72K | -68 | Closed |
|
CARM Hedge Fund Activity: Q4 2020 in Review
56 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q4 2020, worth a combined $37.3M — up 16% from $32.3M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new CARM positions and 3 closed out — a net gain of 11 holders — while 16 added to existing stakes and 11 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.51M. The largest seller was Qube Research & Technologies (QRT), cutting an estimated $383K.
- 56 institutional investors held Carisma Therapeutics (CARM) as of Q4 2020, up from 45 in Q3 2020.
- Funds reported $37.3M of Carisma Therapeutics stock for Q4 2020, up 16% quarter-over-quarter.
- 14 funds opened new Carisma Therapeutics positions in Q4 2020 and 3 closed out, a net change of +11 holders.
- The largest Carisma Therapeutics buyer in Q4 2020 was Vanguard Group, an estimated $1.51M added.
- The largest Carisma Therapeutics seller in Q4 2020 was Qube Research & Technologies (QRT), an estimated $383K sold.
Based on aggregated 13F filings for Q4 2020.